EAU guidelines on testicular cancer: 2011 update.
TL;DR: These guidelines contain information for the standardised management of patients with testicular cancer based on the latest scientific insights, and treatment must be tailored taking individual circumstances and patient preferences into account.
About: This article is published in European Urology.The article was published on 2011-08-01. It has received 328 citations till now. The article focuses on the topics: Testicular cancer & Evidence-based medicine.
Citations
More filters
TL;DR: This publication focuses on the most important changes in treatment recommendations for clinical stage I disease and the updated recommendations for follow-up, which will lead to an overall reduction in treatment burden for patients with germ cell tumours.
515 citations
Cites background from "EAU guidelines on testicular cancer..."
...For unchanged recommendations, the reader is referred to the previous publication of the guidelines in European Urology [7]....
[...]
University of Düsseldorf1, University Medical Center Groningen2, Charité3, Lund University4, Karolinska Institutet5, National Resource Center6, Erasmus University Rotterdam7, Hochschule Hannover8, Institut Gustave Roussy9, Kantonsspital St. Gallen10, The Royal Marsden NHS Foundation Trust11, University of British Columbia12, University of Amsterdam13, Oslo University Hospital14, Paracelsus Private Medical University of Salzburg15, University of Tübingen16, Leipzig University17
TL;DR: The main recommendations and controversies of this meeting are presented, with a particular focus on acute and late toxic effects as well as on survivorship issues.
264 citations
TL;DR: Active surveillance for CSI testis cancer leads to excellent outcomes and the vast majority of relapses occur within 2 years of orchiectomy for CSI nonseminoma and within 3 years for CSI seminoma.
Abstract: Purpose To evaluate the performance of active surveillance as a management strategy in broad populations and to inform the development of surveillance schedules by individual patient data regarding timing and type of relapse. Methods Retrospective study including data from 2,483 clinical stage I (CSI) patients, 1,139 CSI nonseminoma and 1,344 CSI seminoma managed with active surveillance, with the majority treated between 1998 and 2010. Clinical outcomes including relapse and death, time distribution, extent of relapse and method of relapse detection observed on active surveillance were recorded. Results Relapse occurred in 221 (19%) CSI-nonseminoma and 173 (13%) CSI-seminoma patients. Median time to relapse was 4 months (range, 2-61 months), 8 months (range, 2-77 months) and 14 months (range, 2-84 months) for lymphovascular invasion–positive CSI nonseminoma, lymphovascular invasion–negative CSI nonseminoma and CSI seminoma. Most relapses were observed within the first 2 years/3 years after orchiectomy fo...
251 citations
University of St. Gallen1, Queen Mary University of London2, University of Bern3, Karolinska University Hospital4, Copenhagen University Hospital5, University of Paris-Sud6, Oslo University Hospital7, University of Barcelona8, University Medical Center Groningen9, Kantonsspital St. Gallen10, University Hospital of North Norway11, University of Cologne12, German Cancer Research Center13, Institute of Cancer Research14, University Health Network15, University of Düsseldorf16, Akershus University Hospital17, Comenius University in Bratislava18, University Hospital of Basel19, The Royal Marsden NHS Foundation Trust20, Lund University21, Peter MacCallum Cancer Centre22
TL;DR: The aim of the conference was to develop detailed recommendations on topics relating to testicular cancer that are not covered in detail in the current ESMO Clinical Practice Guidelines (CPGs) and where the available level of evidence is insufficient.
218 citations
Cites background from "EAU guidelines on testicular cancer..."
...Salvage treatment generally consists of three to four courses of chemotherapy and possibly RPLND, which results in established patterns of side-effects and late toxicity [98]....
[...]
...Adjuvant carboplatin has only a modest effect in reducing the risk of relapse, and even with two courses of carboplatin, the risk of relapse is reduced from 15%–20% to 3%– 4% [98]....
[...]
TL;DR: In the world's largest study of stage I seminoma patients, surveillance was found to be a safe alternative to adjuvant therapies and tumor size was a significant factor for relapse.
140 citations
Cites background from "EAU guidelines on testicular cancer..."
...These risk factors have subsequently been included in guidelines [1] and are used in risk-adapted treatment [19]....
[...]
References
More filters
01 Jan 1987
TL;DR: Head and Neck Tumours.- Lip and Oral Cavity.- Pharynx.- Larynx.' Maxillary Sinus.- Salivary Glands.- Thyroid Gland.- Digestive System Tumour .
Abstract: Head and Neck Tumours.- Lip and Oral Cavity.- Pharynx.- Larynx.- Maxillary Sinus.- Salivary Glands.- Thyroid Gland.- Digestive System Tumours.- Oesophagus.- Stomach.- Colon and Rectum.- Anal Canal.- Liver.- Gall Bladder.- Extrahepatic Bile Ducts.- Ampulla of Vater.- Pancreas.- Lung Tumours.- Tumours of Bone and Soft Tissues.- Bone.- Soft Tissue.- Skin Tumours.- Carcinoma of Skin.- Melanoma of Skin.- Breast Tumours.- Gynaecological Tumours.- Cervix Uteri.- Corpus Uteri.- Ovary.- Vagina.- Vulva.- Urological Tumours.- Prostate.- Testis.- Penis.- Urinary Bladder.- Kidney.- Renal Pelvis and Ureter.- Urethra.- Ophthalmic Tumours.- Carcinoma of Eyelid.- Malignant Melanoma of Eyelid.- Carcinoma of Conjunctiva.- Malignant Melanoma of Conjunctiva.- Malignant Melanoma of Uvea.- Retinoblastoma.- Sarcoma of Orbit.- Carcinoma of Lacrimal Gland.- Brain Tumours.- Hodgkin's Disease.- Non-Hodgkin's Lymphoma.- Paediatric Tumours.- Nephroblastoma (Wilms' Tumour).- Neuroblastoma.- Soft Tissue Sarcomas - Paediatric.
15,624 citations
4,780 citations
Book•
01 Jan 2004
3,111 citations
2,787 citations
"EAU guidelines on testicular cancer..." refers background or methods in this paper
...Following orchiectomy, pathologic examination of the testis includes the investigations listed in Table 3 [4,20]....
[...]
...The system has been incorporated into the TNM classification and uses histology, location of the primary tumour, location of metastases, and prechemotherapy serum tumour marker levels as prognostic factors to categorise patients into good, intermediate, or poor prognosis [20] (Table 5)....
[...]
...The TNM 2009 staging system is recommended (Table 4) [20]....
[...]